Literature DB >> 14510088

Component therapy.

K M Radhakrishnan1, Srikumar Chakravarthi, S Pushkala, J Jayaraju.   

Abstract

The dramatic advances that have taken place in recent years in the care of sick and premature infants also have been matched by a similar increase in the use of blood transfusion therapy. Haematological features indicate that a newborn has a blood volume of 85-125 ml/kg the foetal haemoglobin is 60-85% and average Hb in full term infant is 18 gm/dl. By 2-3 months it falls to 11-12 g/dl the main cause of anemia are iron poor diet, weaning diets recurrent or chronic infections and hemolytic episodes in malarious areas. The red cells transfusions are usually top up transfusions, exchange transfusions, partial exchange transfusions. Top up- are for investigational losses and correction of mild degrees of anemias, upto to 5-15 ml/kg. They comprise 90% of all neonatal transfusions and are used in low birth babies in special care units for a maximum of 9-10 episodes. The walk in donor programs once popular are not much in vogue. The threshold for transfusion is 8-10 g/dl Hb for upto 5 weeks. Exchange transfusions are done for correction of anemia, removal of bilirubin, removal of antibodies and replacement of red cells. Ideally plasma reduced red cells that are not older than 5 days are used. It is prepared by removal of 120 ml of standard whole blood donation. The advantage of fresh cells is that hyperkalemia is avoided and good post transfusion survival acceptable red cell oxygen affinity. However it has to be screened for sickle cell disease and G6PD deficiency. Indications for exchange transfusion are kernicterus, neonatal hemolysis, G6PD deficiency, ARDS, neonatal sepsis, DIC and neonatal isoimmune thrombocytopaenia. Complications include over transfusion, perforation of major vessels, hypocalcaemia, citrate toxicity, hypothermia, hypoglycaemia, thrombocytopenia, necrotizing enterocolitis, GVHD, bacterial, viral infections. Partial exchange transfusions are done for symptomatic anemia, where Hb<10 g/dl, it is indicated in polycythemia and hyperviscosity syndromes. Exchange volume = Blood volume x (observed Hct-Desired HCt) divided observed Hct. Points to consider-there is weak expression of ABO antigens so particular care while grouping. Transfusing volumes should be 2-5 ml/kg/hour in paediatric bags of 50-100 ml with infusion devices. Platelet transfusion are indicated in neonatal throbocytopaenia, thrombocytopaenia due to sepsis, DIC, bacterial pathogens, CMV, TORCHS, Obstetric conditions such as pre eclampsia, intrauterine death abruption placenta birth injury hypoxia schock neonatal iso immune thrombocytopaenia and maternal ITP. Administration 1 RDE/pack per 2.5 kg single dose of fresh platelets less than 24hrs which contains 55 x 10(9) cells. This also contributes fresh plasma so is useful for coagulation defects also, though there is a risk of CMV and GVHD due to leucocyte contamination. Granulocyte concentrate; Gravity leucopheresis-1:8 ratio of 60 ml of 6% HES made to stand for 1hr.

Entities:  

Mesh:

Year:  2003        PMID: 14510088     DOI: 10.1007/bf02724257

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  16 in total

1.  The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

Authors:  L A GAYDOS; E J FREIREICH; N MANTEL
Journal:  N Engl J Med       Date:  1962-05-03       Impact factor: 91.245

Review 2.  Optimizing platelet transfusions in chronically thrombocytopenic patients.

Authors:  S J Slichter
Journal:  Semin Hematol       Date:  1998-07       Impact factor: 3.851

Review 3.  Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers.

Authors:  D R Norfolk; P J Ancliffe; M Contreras; B J Hunt; S J Machin; W G Murphy; L M Williamson
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

Review 4.  The appropriate use of platelets: an update from the Edinburgh Consensus Conference.

Authors:  M Contreras
Journal:  Br J Haematol       Date:  1998-05       Impact factor: 6.998

Review 5.  Thrombocytopenia: mechanisms and management of defects in platelet production.

Authors:  S J Slichter; L A Harker
Journal:  Clin Haematol       Date:  1978-10

6.  Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

Authors:  J Gmür; J Burger; U Schanz; J Fehr; A Schaffner
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

7.  Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.

Authors:  K D Heckman; G J Weiner; C S Davis; R G Strauss; M P Jones; C P Burns
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

8.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

Authors:  P Rebulla; G Finazzi; F Marangoni; G Avvisati; L Gugliotta; G Tognoni; T Barbui; F Mandelli; G Sirchia
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

9.  Platelet transfusion: a dose-response study.

Authors:  F Norol; P Bierling; F Roudot-Thoraval; F F Le Coeur; C Rieux; A Lavaux; M Kuentz; N Duedari
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

10.  Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients.

Authors:  P T Pisciotto; K Benson; H Hume; A B Glassman; H Oberman; M Popovsky; D Hines; K Anderson
Journal:  Transfusion       Date:  1995-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.